Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck
Background and purpose Patients with locally advanced SCCHN have a poor prognosis. This study investigated the prognostic value of the tumor cell expression of the fibroblast growth factor 2 (FGF-2) in patients treated with surgery followed by radiotherapy. Patients and methods The impact of FGF-2-e...
Gespeichert in:
| Veröffentlicht in: | Strahlentherapie und Onkologie 2014, Vol.190 (1), p.68-74 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 74 |
|---|---|
| container_issue | 1 |
| container_start_page | 68 |
| container_title | Strahlentherapie und Onkologie |
| container_volume | 190 |
| creator | Rades, D. Seibold, N.D. Gebhard, M.P. Noack, F. Schild, S.E. |
| description | Background and purpose
Patients with locally advanced SCCHN have a poor prognosis. This study investigated the prognostic value of the tumor cell expression of the fibroblast growth factor 2 (FGF-2) in patients treated with surgery followed by radiotherapy.
Patients and methods
The impact of FGF-2-expression and 11 additional potential prognostic factors on loco-regional control (LRC), metastases-free survival (MFS), and overall survival (OS) was retrospectively evaluated in 146 patients. Additional factors included age, gender, performance status, pre-radiotherapy hemoglobin levels, tumor site, histologic grade, T-category, N-category, human papilloma virus (HPV) status, extent of resection, and chemotherapy. Univariate analyses were performed with the Kaplan-Meier method and the log-rank test, multivariate analyses with the Cox proportional hazard model.
Results
On multivariate analysis, improved LRC was significantly associated with FGF-2-negativity [risk ratio (RR): 7.33; 95 %-confidence interval (CI): 2.88–19.05; p |
| doi_str_mv | 10.1007/s00066-013-0368-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1468829553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3158996131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-4936581490c25d5e13e49330e4d214e4000b701bb82bcffae290fab4343612ad3</originalsourceid><addsrcrecordid>eNp1kM2KFDEQx4Mo7rj6AF4k4Lm1Kkl_5CiLq8KCFwVvoTpdPdNrT2c2Se-yV5_EZ_HJzDCrePFUUPX_oH5CvER4gwDt2wQATVMB6gp001Xmkdig0bYCa789FhvA1lYt1t2ZeJbSNQA2xpqn4kzprkGs1Ub8uJz6GPqZUpbbGO7yTo7kc4i_fio5JRlGeYhhu4SUJy9vaV5ZjiHKA-WJl5zk3VQsc_A0z_eShltaPA8y3ay0D2uSnudZeop-WsKejnF5x3LHNEhaBrmw__5cPBlpTvziYZ6Lr5fvv1x8rK4-f_h08e6q8rpVuTJWN3WHxoJX9VAzai4rDWwGhYZNYdG3gH3fqd6PI7GyMFJvtNENKhr0uXh9yi0P3aycsrsOa1xKpUPTdJ2yda2LCk8qH0NKkUd3iNOe4r1DcEfq7kTdFeruSN2Z4nn1kLz2ex7-Ov5gLgJ1EqRyWrYc_6n-b-pvbMeOfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1468829553</pqid></control><display><type>article</type><title>Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Rades, D. ; Seibold, N.D. ; Gebhard, M.P. ; Noack, F. ; Schild, S.E.</creator><creatorcontrib>Rades, D. ; Seibold, N.D. ; Gebhard, M.P. ; Noack, F. ; Schild, S.E.</creatorcontrib><description>Background and purpose
Patients with locally advanced SCCHN have a poor prognosis. This study investigated the prognostic value of the tumor cell expression of the fibroblast growth factor 2 (FGF-2) in patients treated with surgery followed by radiotherapy.
Patients and methods
The impact of FGF-2-expression and 11 additional potential prognostic factors on loco-regional control (LRC), metastases-free survival (MFS), and overall survival (OS) was retrospectively evaluated in 146 patients. Additional factors included age, gender, performance status, pre-radiotherapy hemoglobin levels, tumor site, histologic grade, T-category, N-category, human papilloma virus (HPV) status, extent of resection, and chemotherapy. Univariate analyses were performed with the Kaplan-Meier method and the log-rank test, multivariate analyses with the Cox proportional hazard model.
Results
On multivariate analysis, improved LRC was significantly associated with FGF-2-negativity [risk ratio (RR): 7.33; 95 %-confidence interval (CI): 2.88–19.05; p < 0.001], lower T-category (RR: 2.42; 95 %-CI: 1.47–4.33; p < 0.001), lower N-category (RR: 12.36; 95 %-CI: 3.48–78.91; p < 0.001), and pre-radiotherapy hemoglobin levels ≥ 12 g/dl (RR: 4.18; 95 %-CI: 1.73–10.53; p = 0.002). No factor was significantly associated with improved MFS. Lower T-category showed a trend (RR: 1.59; 95 %-CI: 0.97–2.82; p = 0.069). Better OS was significantly associated with FGF-2-negativity (RR: 5.10; 2.22–11.80; p < 0.001), lower T-category (RR: 2.17; 95 %-CI: 1.38–3.68; p < 0.001), lower N-category (RR: 3.86; 95 %-CI: 1.60–10.85; p = 0.002), and pre-radiotherapy hemoglobin levels ≥ 12 g/dl (RR: 3.20; 95 %-CI: 1.46–7.30; p = 0.004). HPV-positivity showed a trend (RR: 2.36; 95 %-CI: n.a.; p = 0.054).
Conclusions
Tumor cell expression of FGF-2 proved to be an independent prognostic factor for LRC and OS. This factor can help personalize treatment and stratify patients in future trials.</description><identifier>ISSN: 0179-7158</identifier><identifier>EISSN: 1439-099X</identifier><identifier>DOI: 10.1007/s00066-013-0368-4</identifier><identifier>PMID: 23861152</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Aged, 80 and over ; Biomarkers, Tumor - analysis ; Carcinoma, Squamous Cell - chemistry ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - therapy ; Female ; Fibroblast Growth Factor 2 - analysis ; Germany - epidemiology ; Head and Neck Neoplasms - chemistry ; Head and Neck Neoplasms - mortality ; Head and Neck Neoplasms - therapy ; Humans ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Prevalence ; Prognosis ; Radiotherapy ; Reproducibility of Results ; Retrospective Studies ; Risk Factors ; Sensitivity and Specificity ; Survival Rate ; Treatment Outcome</subject><ispartof>Strahlentherapie und Onkologie, 2014, Vol.190 (1), p.68-74</ispartof><rights>Springer Heidelberg Berlin 2013</rights><rights>Springer Heidelberg Berlin 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-4936581490c25d5e13e49330e4d214e4000b701bb82bcffae290fab4343612ad3</citedby><cites>FETCH-LOGICAL-c372t-4936581490c25d5e13e49330e4d214e4000b701bb82bcffae290fab4343612ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00066-013-0368-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00066-013-0368-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23861152$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rades, D.</creatorcontrib><creatorcontrib>Seibold, N.D.</creatorcontrib><creatorcontrib>Gebhard, M.P.</creatorcontrib><creatorcontrib>Noack, F.</creatorcontrib><creatorcontrib>Schild, S.E.</creatorcontrib><title>Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck</title><title>Strahlentherapie und Onkologie</title><addtitle>Strahlenther Onkol</addtitle><addtitle>Strahlenther Onkol</addtitle><description>Background and purpose
Patients with locally advanced SCCHN have a poor prognosis. This study investigated the prognostic value of the tumor cell expression of the fibroblast growth factor 2 (FGF-2) in patients treated with surgery followed by radiotherapy.
Patients and methods
The impact of FGF-2-expression and 11 additional potential prognostic factors on loco-regional control (LRC), metastases-free survival (MFS), and overall survival (OS) was retrospectively evaluated in 146 patients. Additional factors included age, gender, performance status, pre-radiotherapy hemoglobin levels, tumor site, histologic grade, T-category, N-category, human papilloma virus (HPV) status, extent of resection, and chemotherapy. Univariate analyses were performed with the Kaplan-Meier method and the log-rank test, multivariate analyses with the Cox proportional hazard model.
Results
On multivariate analysis, improved LRC was significantly associated with FGF-2-negativity [risk ratio (RR): 7.33; 95 %-confidence interval (CI): 2.88–19.05; p < 0.001], lower T-category (RR: 2.42; 95 %-CI: 1.47–4.33; p < 0.001), lower N-category (RR: 12.36; 95 %-CI: 3.48–78.91; p < 0.001), and pre-radiotherapy hemoglobin levels ≥ 12 g/dl (RR: 4.18; 95 %-CI: 1.73–10.53; p = 0.002). No factor was significantly associated with improved MFS. Lower T-category showed a trend (RR: 1.59; 95 %-CI: 0.97–2.82; p = 0.069). Better OS was significantly associated with FGF-2-negativity (RR: 5.10; 2.22–11.80; p < 0.001), lower T-category (RR: 2.17; 95 %-CI: 1.38–3.68; p < 0.001), lower N-category (RR: 3.86; 95 %-CI: 1.60–10.85; p = 0.002), and pre-radiotherapy hemoglobin levels ≥ 12 g/dl (RR: 3.20; 95 %-CI: 1.46–7.30; p = 0.004). HPV-positivity showed a trend (RR: 2.36; 95 %-CI: n.a.; p = 0.054).
Conclusions
Tumor cell expression of FGF-2 proved to be an independent prognostic factor for LRC and OS. This factor can help personalize treatment and stratify patients in future trials.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Carcinoma, Squamous Cell - chemistry</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Female</subject><subject>Fibroblast Growth Factor 2 - analysis</subject><subject>Germany - epidemiology</subject><subject>Head and Neck Neoplasms - chemistry</subject><subject>Head and Neck Neoplasms - mortality</subject><subject>Head and Neck Neoplasms - therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Prevalence</subject><subject>Prognosis</subject><subject>Radiotherapy</subject><subject>Reproducibility of Results</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Sensitivity and Specificity</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0179-7158</issn><issn>1439-099X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kM2KFDEQx4Mo7rj6AF4k4Lm1Kkl_5CiLq8KCFwVvoTpdPdNrT2c2Se-yV5_EZ_HJzDCrePFUUPX_oH5CvER4gwDt2wQATVMB6gp001Xmkdig0bYCa789FhvA1lYt1t2ZeJbSNQA2xpqn4kzprkGs1Ub8uJz6GPqZUpbbGO7yTo7kc4i_fio5JRlGeYhhu4SUJy9vaV5ZjiHKA-WJl5zk3VQsc_A0z_eShltaPA8y3ay0D2uSnudZeop-WsKejnF5x3LHNEhaBrmw__5cPBlpTvziYZ6Lr5fvv1x8rK4-f_h08e6q8rpVuTJWN3WHxoJX9VAzai4rDWwGhYZNYdG3gH3fqd6PI7GyMFJvtNENKhr0uXh9yi0P3aycsrsOa1xKpUPTdJ2yda2LCk8qH0NKkUd3iNOe4r1DcEfq7kTdFeruSN2Z4nn1kLz2ex7-Ov5gLgJ1EqRyWrYc_6n-b-pvbMeOfg</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Rades, D.</creator><creator>Seibold, N.D.</creator><creator>Gebhard, M.P.</creator><creator>Noack, F.</creator><creator>Schild, S.E.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>2014</creationdate><title>Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck</title><author>Rades, D. ; Seibold, N.D. ; Gebhard, M.P. ; Noack, F. ; Schild, S.E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-4936581490c25d5e13e49330e4d214e4000b701bb82bcffae290fab4343612ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Carcinoma, Squamous Cell - chemistry</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Female</topic><topic>Fibroblast Growth Factor 2 - analysis</topic><topic>Germany - epidemiology</topic><topic>Head and Neck Neoplasms - chemistry</topic><topic>Head and Neck Neoplasms - mortality</topic><topic>Head and Neck Neoplasms - therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Prevalence</topic><topic>Prognosis</topic><topic>Radiotherapy</topic><topic>Reproducibility of Results</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Sensitivity and Specificity</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rades, D.</creatorcontrib><creatorcontrib>Seibold, N.D.</creatorcontrib><creatorcontrib>Gebhard, M.P.</creatorcontrib><creatorcontrib>Noack, F.</creatorcontrib><creatorcontrib>Schild, S.E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Strahlentherapie und Onkologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rades, D.</au><au>Seibold, N.D.</au><au>Gebhard, M.P.</au><au>Noack, F.</au><au>Schild, S.E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck</atitle><jtitle>Strahlentherapie und Onkologie</jtitle><stitle>Strahlenther Onkol</stitle><addtitle>Strahlenther Onkol</addtitle><date>2014</date><risdate>2014</risdate><volume>190</volume><issue>1</issue><spage>68</spage><epage>74</epage><pages>68-74</pages><issn>0179-7158</issn><eissn>1439-099X</eissn><abstract>Background and purpose
Patients with locally advanced SCCHN have a poor prognosis. This study investigated the prognostic value of the tumor cell expression of the fibroblast growth factor 2 (FGF-2) in patients treated with surgery followed by radiotherapy.
Patients and methods
The impact of FGF-2-expression and 11 additional potential prognostic factors on loco-regional control (LRC), metastases-free survival (MFS), and overall survival (OS) was retrospectively evaluated in 146 patients. Additional factors included age, gender, performance status, pre-radiotherapy hemoglobin levels, tumor site, histologic grade, T-category, N-category, human papilloma virus (HPV) status, extent of resection, and chemotherapy. Univariate analyses were performed with the Kaplan-Meier method and the log-rank test, multivariate analyses with the Cox proportional hazard model.
Results
On multivariate analysis, improved LRC was significantly associated with FGF-2-negativity [risk ratio (RR): 7.33; 95 %-confidence interval (CI): 2.88–19.05; p < 0.001], lower T-category (RR: 2.42; 95 %-CI: 1.47–4.33; p < 0.001), lower N-category (RR: 12.36; 95 %-CI: 3.48–78.91; p < 0.001), and pre-radiotherapy hemoglobin levels ≥ 12 g/dl (RR: 4.18; 95 %-CI: 1.73–10.53; p = 0.002). No factor was significantly associated with improved MFS. Lower T-category showed a trend (RR: 1.59; 95 %-CI: 0.97–2.82; p = 0.069). Better OS was significantly associated with FGF-2-negativity (RR: 5.10; 2.22–11.80; p < 0.001), lower T-category (RR: 2.17; 95 %-CI: 1.38–3.68; p < 0.001), lower N-category (RR: 3.86; 95 %-CI: 1.60–10.85; p = 0.002), and pre-radiotherapy hemoglobin levels ≥ 12 g/dl (RR: 3.20; 95 %-CI: 1.46–7.30; p = 0.004). HPV-positivity showed a trend (RR: 2.36; 95 %-CI: n.a.; p = 0.054).
Conclusions
Tumor cell expression of FGF-2 proved to be an independent prognostic factor for LRC and OS. This factor can help personalize treatment and stratify patients in future trials.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>23861152</pmid><doi>10.1007/s00066-013-0368-4</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0179-7158 |
| ispartof | Strahlentherapie und Onkologie, 2014, Vol.190 (1), p.68-74 |
| issn | 0179-7158 1439-099X |
| language | eng |
| recordid | cdi_proquest_journals_1468829553 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Aged Aged, 80 and over Biomarkers, Tumor - analysis Carcinoma, Squamous Cell - chemistry Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - therapy Female Fibroblast Growth Factor 2 - analysis Germany - epidemiology Head and Neck Neoplasms - chemistry Head and Neck Neoplasms - mortality Head and Neck Neoplasms - therapy Humans Male Medicine Medicine & Public Health Middle Aged Oncology Original Article Prevalence Prognosis Radiotherapy Reproducibility of Results Retrospective Studies Risk Factors Sensitivity and Specificity Survival Rate Treatment Outcome |
| title | Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T18%3A57%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fibroblast%20growth%20factor%C2%A02%20is%20of%20prognostic%20value%20for%20patients%20with%20locally%20advanced%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck&rft.jtitle=Strahlentherapie%20und%20Onkologie&rft.au=Rades,%20D.&rft.date=2014&rft.volume=190&rft.issue=1&rft.spage=68&rft.epage=74&rft.pages=68-74&rft.issn=0179-7158&rft.eissn=1439-099X&rft_id=info:doi/10.1007/s00066-013-0368-4&rft_dat=%3Cproquest_cross%3E3158996131%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1468829553&rft_id=info:pmid/23861152&rfr_iscdi=true |